TY  - GEN
AU  - Tout,Mira
AU  - Gagez,Anne-Laure
AU  - Leprêtre,Stéphane
AU  - Gouilleux-Gruart,Valérie
AU  - Azzopardi,Nicolas
AU  - Delmer,Alain
AU  - Mercier,Mélanie
AU  - Ysebaert,Loïc
AU  - Laribi,Kamel
AU  - Gonzalez,Hugo
AU  - Paintaud,Gilles
AU  - Cartron,Guillaume
AU  - Ternant,David
TI  - Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group
SN  - 1179-1926
PY  - 2018///0221
KW  - Antigens, CD20
KW  - metabolism
KW  - Antineoplastic Agents
KW  - blood
KW  - B-Lymphocytes
KW  - Body Surface Area
KW  - Female
KW  - Genotype
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - drug therapy
KW  - Lymphocyte Count
KW  - Male
KW  - Middle Aged
KW  - Models, Biological
KW  - Polymorphism, Genetic
KW  - Receptors, IgG
KW  - genetics
KW  - Rituximab
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s40262-016-0470-8
ER  -